As previously reported, Stifel analyst Thomas Shrader set a Buy rating and $16 price target on Alpine Immune Sciences (ALPN), the "financial continuation" of Nivalis. That is up from the prior rating of Hold and $3.25 on its predecessor. He sees the company's focus on immune system modulation as a "timely and a powerful approach" to build additional specificity into current immunomodulatory drugs. Shrader adds that the company's collaboration with Kite Pharma (KITE) seems "more important than ever" after Gilead (GILD) comments that they plan to use excess R&D capacity to "keep up" in the evolving CAR-T/TCR space.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Alpine Immune Sciences (ALPN) 11.31% +11.06, Corebridge Financial (CRBG) 11.31% +10.76, Lithium Americas (LAC) 45.91% +1.55, Direxion Daily 20 plus Year Treasury Bear 3X Shares (TMV) 8.88% +0.67, Crescent Point Energy (CPG) 0.80% +0.32, Enovix (ENVX) 7.97% +0.29, Taseko Mines (TGB) 1.81% +0.27, Valkyrie Bitcoin Miners ETF (WGMI) 2.30% +0.25, KULR Technology Group (KULR) 7.39% +0.24, and B Riley Financial (RILY) 64.62% +0.20.